| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.083 | 0.07 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.27 | 0.08 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.086 | 0.08 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.098 | 0.08 |